Former U.S. Bioscience CEO Boyd Clarke named president and CEO of the Mountain View, Calif.-based company. Aviron founder and CEO Leighton Read will remain chairman. Aviron's BLA filing plans for the nasal flu vaccine Flumist were delayed in November due to manufacturing difficulties (1"The Pink Sheet" Nov. 22, p. 18). U.S. Bioscience was recently acquired by MedImmune
You may also be interested in...
Production of Medeva's influenza vaccine Fluvirin has returned to levels of market demand following improvements in the manufacturing process, the company said.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials